• Alkermes reported interim long-term extension results showing alixorexton sustained clinically meaningful improvements in wakefulness and sleepiness in narcolepsy.
• At week 24 of the extension, mean MWT sleep latency reached about 29 minutes in narcolepsy type 1; mean ESS was 7.5.
• Narcolepsy type 2 participants showed mean MWT sleep latency of about 18 minutes; mean ESS was 8.9 at week 24.
• No serious treatment-emergent adverse events were reported; alixorexton was generally well tolerated across doses.
• Alixorexton remains in phase 3 Brilliance studies for narcolepsy type 1 and type 2; phase 2 Vibrance-3 in idiopathic hypersomnia continues.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202607130700BIZWIRE_USPR_____20260713_BW390823) on July 13, 2026, and is solely responsible for the information contained therein.